Tasgen Biotech

Tasgen Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, and a key subsidiary of Tasly Biopharmaceuticals. The company focuses on the development and commercialization of high-quality biologics, including recombinant proteins and monoclonal antibodies, primarily targeting metabolic diseases and oncology. Its pipeline features advanced candidates such as insulin glargine and GLP-1 fusion proteins for diabetes, as well as biosimilar and novel antibody programs for cancer. Tasgen leverages a robust mammalian cell expression platform and large-scale GMP manufacturing capabilities to support its internal R&D and potential CDMO services. The company aims to provide affordable and innovative therapeutic solutions to patients globally through its integrated R&D and production system.